Sudden deafness
Conditions
Interventions
Group A:Batroxobin + methylprednisolone intravenous injection
Group B:Methylprednisolone intravenous injection + dexamethasone injection
Group C:Batroxobin + methylprednisolone intravenous injection + dexamethasone tympanic injection
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Comply with the diagnostic criteria in the U.S. "Guidelines for the Diagnosis and Treatment of Sudden Deafness (2019)"; 2. Age over 18 years old, regardless of gender; 3. Onset of one ear; 4. Onset within 2 weeks, first diagnosis and treatment and hospitalization; 5. Obtained Written informed consent was obtained.
Exclusion criteria
Exclusion criteria: 1. History of middle ear and inner ear surgery; congenital deafness, conductive deafness, presbycusis, explosive deafness, drug-induced deafness, large vestibular aqueduct syndrome, Meniere's disease, Deafness accompanied by systemic genetic diseases, space-occupying diseases of the cochlea and cerebellopontine angle, and sudden deafness caused by traumatic lymphatic atrophy, syphilis infection, cerebrovascular accident, etc.; 2. Children, pregnant and lactating women , Those who are allergic or contraindicated to the study drugs (such as active ulcers, mental disorders, epilepsy, tuberculosis, adrenal hyperfunction, etc.); 3. have serious systemic diseases (such as severe hypertension, diabetes due to There are hormone contraindications, so it is ruled out), language barriers, and those who cannot complete the treatment according to the pre-designed clinical trial protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone listening;Tinnitus symptoms;Ear stuffy symptoms;Vertigo symptoms; | — |
Countries
China
Contacts
Public ContactXiaowen Zhang
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed